Assignee
HEIDELBERG PHARMA RES GMBH
DE·19 granted patents·17 pending applications·7 citations·filing 2016–2025
Top patents by PatentIndex Score
36 records- 0185US12251448B2Compositions and methods for the depletion of CD5+ cellsHEIDELBERG PHARMA RES GMBH·Filed 2021·Granted Mar 18, 2025·1 cites·13 claims
- 0280US11583569B2PSMA-targeting amanitin conjugatesHEIDELBERG PHARMA RES GMBH·Filed 2018·Granted Feb 21, 2023·2 cites·18 claims
- 0377US2025082767A1Compositions and methods for the depletion of cd5+ cellsHEIDELBERG PHARMA RES GMBH·Filed 2024·Application pending·0 cites
- 0475US11420971B2Method for synthesizing amanitinsHEIDELBERG PHARMA RES GMBH·Filed 2018·Granted Aug 23, 2022·1 cites·8 claims
- 0575US10961277B2Method for synthesizing amanitinsHEIDELBERG PHARMA RES GMBH·Filed 2018·Granted Mar 30, 2021·1 cites·9 claims
- 0675US2025064960A1B-lymphocyte specific amatoxin antibody conjugatesHEIDELBERG PHARMA RES GMBH·Filed 2024·Application pending·0 cites
- 0774US12201693B2Amanitin conjugatesHEIDELBERG PHARMA RES GMBH·Filed 2023·Granted Jan 21, 2025·0 cites·5 claims
- 0873US11590238B2Amanitin conjugatesHEIDELBERG PHARMA RES GMBH·Filed 2017·Granted Feb 28, 2023·1 cites·6 claims
- 0973US2026000780A1B-lymphocyte specific amatoxin antibody conjugatesHEIDELBERG PHARMA RES GMBH·Filed 2025·Application pending·0 cites
- 1072US2025009901A1Composition comprising a combination of immune checkpoint inhibitor and antibody-amatoxin conjugate for use in cancer therapyHEIDELBERG PHARMA RES GMBH·Filed 2024·Application pending·0 cites
- 1171US12403201B2B-lymphocyte specific amatoxin antibody conjugatesHEIDELBERG PHARMA RES GMBH·Filed 2022·Granted Sep 2, 2025·0 cites·8 claims
- 1271US2026078148A1Amatoxin antibody-drug conjugates and uses thereofHEIDELBERG PHARMA RES GMBH·Filed 2025·Application pending·0 cites
- 1371US2026097093A1Targeted amatoxin conjugate for the treatment of solid tumorsHEIDELBERG PHARMA RES GMBH·Filed 2025·Application pending·0 cites
- 1470US11926631B2Method of treating cancer using amanitin derivativesHEIDELBERG PHARMA RES GMBH·Filed 2022·Granted Mar 12, 2024·0 cites·4 claims
- 1568US11446388B2Amanitin antibody conjugatesHEIDELBERG PHARMA RES GMBH·Filed 2017·Granted Sep 20, 2022·1 cites·3 claims
- 1667US2025186606A1Modular linker compound for target-binding drug conjugatesHEIDELBERG PHARMA RES GMBH·Filed 2024·Application pending·0 cites
- 1765US12378196B2Synthesis of (S)-6-hydroxytryptophan and derivatives thereofHEIDELBERG PHARMA RES GMBH·Filed 2019·Granted Aug 5, 2025·0 cites·16 claims
- 1864US11702451B2Method for synthesizing amanitinsHEIDELBERG PHARMA RES GMBH·Filed 2021·Granted Jul 18, 2023·0 cites·20 claims
- 1963US2025195675A1New antibody-drug conjugate as well as methods of production and uses thereofHEIDELBERG PHARMA RES GMBH·Filed 2024·Application pending·0 cites
- 2063US2024307549A1Subcutaneously administered antibody-drug conjugates for use in cancer treatmentHEIDELBERG PHARMA RES GMBH·Filed 2024·Application pending·0 cites
- 2162US2024165257A1Anti-gucy2c antibody and uses thereofHEIDELBERG PHARMA RES GMBH·Filed 2023·Application pending·0 cites
- 2261US12595284B2Amatoxin antibody-drug conjugates and uses thereofHEIDELBERG PHARMA RES GMBH·Filed 2020·Granted Apr 7, 2026·0 cites·18 claims
- 2361US2022133902A1Composition Comprising a Combination of Immune Checkpoint Inhibitor and Antibody-Amatoxin Conjugate for Use in Cancer TherapyHEIDELBERG PHARMA RES GMBH·Filed 2021·Application pending·0 cites
- 2460US2023355792A1Methods of improving the therapeutic indexHEIDELBERG PHARMA RES GMBH·Filed 2023·Application pending·0 cites
- 2558US2025171419A1Novel nicotinamide phosphoribosyltransferase inhibitors and uses thereofHEIDELBERG PHARMA RES GMBH·Filed 2024·Application pending·0 cites
- 2655US12006370B2Use of anti-CD5 antibody drug conjugate (ADC) in allogeneic cell therapyHEIDELBERG PHARMA RES GMBH·Filed 2021·Granted Jun 11, 2024·0 cites·30 claims
- 2755US2025179018A1Synthesis of (s)-6-hydroxytryptophan and derivatives thereofHEIDELBERG PHARMA RES GMBH·Filed 2025·Application pending·0 cites
- 2854US12403185B2Use of anti-CD137 antibody drug conjugate (ADC) in allogeneic cell therapyHEIDELBERG PHARMA RES GMBH·Filed 2021·Granted Sep 2, 2025·0 cites·23 claims
- 2952US12544419B2Targeted amatoxin conjugate for the treatment of solid tumorsHEIDELBERG PHARMA RES GMBH·Filed 2019·Granted Feb 10, 2026·0 cites·7 claims
- 3051US11976131B2Humanized antibodies against PSMAHEIDELBERG PHARMA RES GMBH·Filed 2019·Granted May 7, 2024·0 cites·20 claims
- 3149US10723766B2Derivatives of gamma-amanitinHEIDELBERG PHARMA RES GMBH·Filed 2016·Granted Jul 28, 2020·0 cites·4 claims
- 3248US2025195678A1B-lymphocyte specific amatoxin antibody conjugatesHEIDELBERG PHARMA RES GMBH·Filed 2020·Application pending·0 cites
- 3347US12576158B2Antibody drug conjugates with cleavable linkersHEIDELBERG PHARMA RES GMBH·Filed 2020·Granted Mar 17, 2026·0 cites·22 claims
- 3445US2023220001A1Method for synthesis of thioether-containing peptidesHEIDELBERG PHARMA RES GMBH·Filed 2021·Application pending·0 cites
- 3539US2023039142A1Synthesis of amanin and its derivativesHEIDELBERG PHARMA RES GMBH·Filed 2020·Application pending·0 cites
- 3629US11584708B2Synthesis of (2S,3R,4R)-4,5-dihydroxyisoleucine and derivativesHEIDELBERG PHARMA RES GMBH·Filed 2019·Granted Feb 21, 2023·0 cites·11 claims
Join the waitlist — get patent alerts
Get an alert when HEIDELBERG PHARMA RES GMBH files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →